Drugs in Dev. Oncology
Undisclosed
Sweden 
Lead Product(s) : Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Company has announced the initiation of developing two new biosimilar candidates referencing Keytruda® and Darzalex® respectively. Together with Xdivane™, these new biosimilar candidates form an oncology biosimilar portfolio.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
December 13, 2021
Lead Product(s) : Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Rheos Medicines
Deal Size : Inapplicable
Deal Type : Inapplicable
A Joint Patent Application For MALT1 Inhibitors Published
Details : The patent application is an outcome of the option agreement that was previously entered into between the two companies regarding Medivir’s preclinical MALT1 project.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
October 15, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Rheos Medicines
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dasatinib
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Xspray Pharma Reports Positive Results From a Study with Dasatinib During Omeprazole Treatment
Details : Xspray Pharma has received positive preliminary results from a bioavailability study in healthy volunteers with an improved HyNap-Dasa version of the reference drug Sprycel™, demonstrating that absorption of HyNap-Dasa is not dependent on the gastric p...
Product Name : Dasynoc
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 30, 2020
Lead Product(s) : Dasatinib
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Melphalan Flufenamide
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Melphalan Flufenamide is a Peptide drug candidate, which is currently being evaluated in clinical studies for the treatment of Multiple Myeloma.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
September 01, 2020
Lead Product(s) : Melphalan Flufenamide
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mitazalimab,SCO-101
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Scandion Oncology
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The two companies will explore the anti-tumor effect of the CD40 antibody mitazalimab (Alligator Bioscience) in combination with SCO-101 (Scandion Oncology) as an add-on to chemotherapy in preclinical tumor models that have been shown to be resistant to ...
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
June 04, 2020
Lead Product(s) : Mitazalimab,SCO-101
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Scandion Oncology
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Biotheus
Deal Size : Undisclosed
Deal Type : Collaboration
Alligator Bioscience's Collaboration With Biotheus Inc. Proceeds and Second Payment is Received
Details : The license agreement includes exclusive rights to an immune-activating antibody directed against a receptor within the TNFR-SF, a collective name for a number of target molecules with similar functions, and applies to the China, Hong Kong, Taiwan and Ma...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
June 01, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Biotheus
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Undisclosed
Deal Type : Agreement
BioInvent Signs Manufacturing Agreement With US Cell Therapy Company
Details : The agreement, for an undisclosed amount, includes process development and conjugation of two antibodies in BioInvent's development labs with work expected to start in May 2020.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
April 30, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Undisclosed
Deal Type : Agreement
Reset All
